Generic immunosuppressant use in solid organ transplantation.
Although economics may be the driving force for generic development, these forces must be tempered by consumer safety and efficacy. Studies to date imply that we are gaining balance in attempts to reconcile these issues. With the development of more generic immunosuppressants imminent, the transplant community must continue to enforce their high standards of a research driven discipline where the transition from research to clinical practice is often seamless. Higher academic demands will continue to be expected for any generic developed for use in transplantation. Whether or not generic availability will subsequently impact other areas of transplantation such as legislative policies for reimbursement, compliance, and long-term graft survival has not been quantified and requires further study.
D001379:Azathioprine / Q000493:pharmacokinetics / Q000627:therapeutic use; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000627:therapeutic use; D016568:Drugs, Generic / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016377:Organ Transplantation; D011241:Prednisone / Q000493:pharmacokinetics / Q000627:therapeutic use; D013810:Therapeutic Equivalency